MTA3 and melanoma: Our discoveries also illustrated that SPHK1-MTA3 maintains the immunosuppressive status in the TME and promotes tumor immune escape by positively regulating PD-L1 on melanoma cells, decreasing the proportion of TILs, and inhibiting tumor-specific CTL activation in an independent manner.